Momenta Pharma (MNTA) Posts Q3 Loss of $0.38, Tops by 2c
More News related to MNTA
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Momenta Pharmaceuticals (MNTA) Dec volatility at 89, March at 121 into FDA
- Oppenheimer Upgrades Momenta Pharmaceuticals (MNTA) to Outperform
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Canaccord Adams Initiates Coverage on Momenta Pharmaceuticals (MNTA) with a Buy
More News related to Earnings
- Sprint Nextel (S) Completes Tender Offer for iPCS, Inc. (IPCS)
- Ford (F) and Geely Reportedly Clear Hurdle On Possible Volvo Deal
- Starent Networks (STAR) To Settle Shareholder Class Action Suit In Connection With Proposed Merger with Cisco (CSCO)
- Hurray! Holding (HRAY) To Acquire Ku6 in All Stock Transaction
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) reports Q3 loss of $0.38, 2 cents better than the analyst estimate of ($0.40). Revenue for the quarter was $4 million, which compares to the estimate of $4.74 million.
Related Categories
EarningsStocks Mentioned
-0.40Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
